AI Article Synopsis
- The study focused on understanding what factors influence influenza vaccination rates among 1,945 adult cancer survivors in Korea.
- Overall, around 60.8% of participants reported receiving the vaccine, with younger survivors significantly less likely to be vaccinated compared to older survivors (54.73% vs. 80.22%).
- Factors like time since cancer diagnosis, lifestyle counseling, and exercise were linked to higher vaccination rates in younger survivors, while conditions like multimodality treatment and education level were negatively associated; fewer factors influenced vaccination in elderly survivors.
- The findings suggest a need for targeted strategies to boost vaccination rates in younger cancer survivors by considering their unique characteristics.
Article Abstract
Objective: To investigate factors associated with influenza vaccination in cancer survivors.
Methods: Study subjects were 1,945 Korean adult cancer survivors. Through medical record review and self-administered questionnaires, social and medical information was collected. Influenza vaccination was defined as ever having received a flu vaccine between one year before cancer diagnosis and the survey date. Multiple logistic regression analysis was used to evaluate factors associated with influenza vaccination.
Results: Overall, 60.8% of study subjects had received an influenza vaccination. Younger survivors had a significantly lower vaccination rate than did the elderly survivors (80.22% vs. 54.73%). In younger survivors, longer time elapsed since cancer diagnosis, lifestyle modification counselling during cancer treatment, adequate physical exercise (≥150 min/week) and complementary medication use were positively associated with vaccination, whereas extra-pulmonary cancers, multimodality (≥3) cancer treatment and higher educational achievement were inversely associated. In elderly survivors, fewer factors had a positive (adequate physical exercise) or inverse (multimodality cancer treatment and current smoking) association with influenza vaccination.
Conclusion: Influenza vaccination rate was suboptimal, especially among younger cancer survivors. Targeted strategies are necessary to improve influenza vaccination in cancer survivors with consideration of individual characteristics such as age, lifestyle, cancer treatment modality, cancer type and education level.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ecc.13443 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synthesizing and assessing influenza vaccine evidence: Strengths and limitations of the recent ECDC report on the effectiveness of new and enhanced influenza vaccines. Communication on: the "European Centre for Disease Prevention and Control. Systematic review update on the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory confirmed influenza in individuals aged 18 years and over. Stockholm: ECDC; 2024".
Germs
September 2024
MD, FESPCH, Prof., General Practitioner, Röntgenstr. 2 82152 Martinsried, Germany.
High quality research is critical for evidence-based decision making in public health and fundamental to maintain progress and trust in immunization programs in Europe. In 2024 the European Centre for Disease Prevention and Control (ECDC) conducted an update of the 2020 systematic review to capture more recent evidence on of the efficacy, effectiveness of influenza vaccines in individuals aged 18 years and older in the prevention of laboratory-confirmed influenza. While this report was highly anticipated due to the strength of the protocol and processes put in place, during our assessment, we expressed two chief concerns.
View Article and Find Full Text PDFLessons Learned from a Quality Improvement Initiative to Increase COVID-19 Vaccination in Hospitalized Children.
Pediatr Qual Saf
January 2025
Department of Pediatrics, Washington University in St. Louis School of Medicine, St. Louis, Mo.
Introduction: Pediatric coronavirus disease 2019 (COVID-19) vaccination rates in the United States remain lower compared with adults. We aimed to (1) implement a quality improvement initiative to increase COVID-19 vaccination 2-fold in hospitalized patients 12-21 years of age from 4.7% during the baseline period (August 10, 2021-November 1, 2021) to 9.
View Article and Find Full Text PDFHigh dose inactivated influenza vaccine inconsistently improves heterologous antibody responses in an elderly human cohort.
J Infect Dis
January 2025
College of Public Health, University of Georgia, Athens, GA, USA.
Background: Older adults often mount a weak immune response to standard inactivated influenza vaccines. To induce a stronger response and better protection, a high-dose (HD) version of the inactivated Fluzone vaccine is recommended for individuals >65 years of age. While better immunogenicity and protection against the vaccine strain has been shown, it is not known if the HD vaccine also induces a robust antibody response to heterologous strains.
View Article and Find Full Text PDFInfluenza and Aging: Clinical Manifestations, Complications, and Treatment Approaches in Older Adults.
Drugs Aging
January 2025
University Hospitals of Cleveland, 11100 Euclid Ave, Mailstop 5083, Cleveland, OH, 44106, USA.
Influenza, a highly contagious respiratory viral illness, poses significant global health risks, particularly affecting older and those with chronic health conditions. Influenza viruses, primarily types A and B, are responsible for seasonal human infections and exhibit a propensity for antigenic drift and shift, contributing to seasonal epidemics and pandemics. The severity of influenza varies, but severe cases often lead to pneumonia, acute respiratory distress syndrome, and multiorgan failure.
View Article and Find Full Text PDFImmunogenicity and safety of the MF59-adjuvanted seasonal influenza vaccine in non-elderly adults: A systematic review and meta-analysis.
PLoS One
December 2024
Seqirus S.r.l., Monteriggioni (Siena), Italy.
Objective: In Europe, the age indication for the MF59-adjuvanted quadrivalent influenza vaccine (aQIV) has recently been extended from ≥65 to ≥50 years. Considering that the earliest approval of its trivalent formulation (aTIV) in Italy was for people aged ≥12 years, we aimed to systematically appraise data on the immunogenicity, efficacy, and safety of aTIV/aQIV in non-elderly adults.
Methods: A systematic literature review was conducted according to the available guidelines and studies were searched in MEDLINE, Biological Abstracts, Web of Science, Cochrane Library and clinical trial registries.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!